Arrowhead Pharmaceuticals, Inc. (ARWR) Analysts See $-0.19 EPS

July 11, 2018 - By Ellis Scott

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

Analysts expect Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to report $-0.19 EPS on August, 2.They anticipate $0.12 EPS change or 171.43 % from last quarter’s $-0.07 EPS. After having $-0.18 EPS previously, Arrowhead Pharmaceuticals, Inc.’s analysts see 5.56 % EPS growth. The stock increased 1.92% or $0.31 during the last trading session, reaching $16.42. About 1.24M shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 540.13% since July 12, 2017 and is uptrending. It has outperformed by 527.56% the S&P500.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 5 analysts covering Arrowhead Pharmaceuticals (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Arrowhead Pharmaceuticals had 10 analyst reports since February 12, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Monday, March 12 by FBR Capital. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Neutral” rating by Cantor Fitzgerald on Monday, February 12. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Buy” rating by Cantor Fitzgerald on Monday, June 18. The firm earned “Hold” rating on Tuesday, March 27 by FBR Capital. Cantor Fitzgerald upgraded Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Wednesday, May 9 to “Overweight” rating. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Buy” rating by Cantor Fitzgerald on Wednesday, May 30. On Monday, February 12 the stock rating was maintained by FBR Capital with “Hold”. The firm has “Neutral” rating given on Monday, February 12 by B. Riley & Co.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company has market cap of $1.44 billion. The Company’s pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. It currently has negative earnings. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.

More news for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were recently published by: Fool.com, which released: “Why Arrowhead Pharmaceuticals Stock Is Skyrocketing 23.3% Today” on June 18, 2018. Fool.com‘s article titled: “3 Huge Biotech Winners in 2018 (So Far)” and published on July 11, 2018 is yet another important article.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>